Claims can reveal when a patient fills a prescription or undergoes a procedure that was billed to their insurance, but for obesity care they rarely capture the clinical details that define treatment response
Scheda del composto Taurina su PubChem. Disponibile allindirizzo: Centro Nazionale per le Informazioni Biotecnologiche (NCBI)
Related analysis & solutions FEATURED ANALYSIS WHAT YOUR BRAND NEEDS TO KNOW NOW Track MAHA pharma risk
For us, GLP-1s, last year, were number 32, and this year theyre number one [in pharmacy spending]. Human Resources Director, health benefits administrator Before we knew it, we spent half a million dollars and were projected to go up to $1.2 million the following year. Manager of Compensation and Benefits Administration, large retail firm Ill just say our GLP-1 agonist spending year over year was increasing 50% for weight loss
A p-value less than 0.05 was considered to be significant
These results suggest a potential regulatory relationship between thymosin beta 4, microRNA 146a expression, and downstream inflammatory pathway modulation
